Shares of Dexcom (NASDAQ:DXCM), a medical device company specializing in glucose monitoring systems, saw a significant increase of 5% following the announcement of its 2025 revenue forecast.
The company preannounced fourth-quarter sales that exceeded expectations, reporting $1.113 billion compared to the Street's anticipation of $1.096 billion.
Looking ahead, Dexcom set its 2025 guidance with projected sales of $4.6 billion, gross margins around 64.5%, and operating margins approximately 21%.
The 2025 revenue forecast aligns with current market expectations, indicating confidence in the company's strategic direction and operational targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Should you invest $2,000 in DXCM right now?
ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is DXCM one of them?
Unlock ProPicks AI to find out